Roquefort Investments PLC Board Changes (5782P)
20 Octubre 2021 - 01:00AM
UK Regulatory
TIDMROQ
RNS Number : 5782P
Roquefort Investments PLC
20 October 2021
20 October 2021
Roquefort Investments plc
("Roquefort Investments" or the "Company")
Board Changes
Roquefort Investments ( LSE:ROQ ), the investment company
established to acquire businesses focused on early-stage
opportunities in the medical biotechnology sector , announces the
appointment of Mr Mark Freeman as a non-executive director and the
resignation of Mr Glenn Whiddon as non-executive director with
effect from today.
Mr Freeman (aged 46) is a Chartered Accountant and has more than
25 years' experience in corporate finance and the public markets,
with a focus on project development. Mr Freeman is a graduate of
the University of Western Australia with a Bachelor of Commerce
with a double major in Banking & Finance and Accounting as well
as holding a Graduate Diploma in Applied Finance with a major in
Investment Analysis from the Securities Institute of Australia. He
has experience in strategic planning, business development,
acquisitions and mergers, project commercialisation, project
development and general management. Mr Freeman is currently a
director of Pursuit Minerals Ltd (ASX:PUR), Calima Energy Ltd
(ASX:CE1) and Grand Gulf Energy Ltd (ASX:GGE).
In addition, Mr Freeman is currently a director of Lyramid
Limited ("Lyramid"). It is intended that Mr Freeman will retain his
position as one of the two Australian resident directors required
to be appointed to the Board of Lyramid after the proposed
acquisition of Lyramid has completed.
Stephen West, Executive Chairman, commented:
"As we work towards completion of the Lyramid transaction, it is
important to have a financially oritentated Australian resident
director with public markets experience to assist the Company going
forward. We are therefore delighted that Mark Freeman has agreed to
join the Company as a non-executive director given his proven track
record and experience in this regard. I would like to thank Glenn
Whiddon for working with us from the formation of Roquefort
Investments up to this transformational stage for the Company.
The Board is focused on completing the Lyramid transaction and
the RTO process and we look forward to providing a further update
on this shortly."
Enquiries:
Roquefort Investments plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Optiva Securities Limited (Joint
Broker)
+44 (0) 20 3411
Christian Dennis 1881
For further information, please visit www.roquefortinvest.com
and @roquefortinvest on Twitter.
LEI: 254900P4SISIWOR9RH34
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFFEFIUEFSEIS
(END) Dow Jones Newswires
October 20, 2021 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024